联合国儿童基金会和总部位于日内瓦的全球疫苗组织Gavi周四表示，他们已达成协议，将Mosquirix疟疾疫苗价格降低约40%。以下是更多细节：该协议由联合国儿童基金会执行，并由Gavi提供资金支持，预计在2027年至2029年间节省约5000万美元，并将疫苗价格降至每剂5.50欧元（6.16美元）。该疫苗名为Mosquirix或RTS,S/AS01，由GSK（GSK.L）和非营利组织PATH开发，目前正从GSK转移至Bharat Biotech以供未来供应。
UNICEF and Geneva-based global vaccine group Gavi said on Thursday that they have reached an agreement to cut the price of the Mosquirix malaria vaccine by about 40%. Here are more details: The deal, executed by UNICEF and financially backed by Gavi, is expected to generate around $50 million in savings between 2027 and 2029 and will bring the price of the vaccine down to €5.50 ($6.16) per dose The vaccine, called Mosquirix or RTS,S/AS01, developed by GSK (GSK.L) and the non-profit PATH and is now being transferred from GSK to Bharat Biotech for future supply GSK is working on a technology transfer to Bharat Biotech, and will continue to supply the adjuvant part of the vaccine to Bharat when the Indian drugmaker fully takes over production of the shot by 2028 The lower price is expected to take effect by early 2027, and it builds on the transfer of the vaccine’s production to a developing-country manufacturer, Gavi and UNICEF said The agreement is subject to regulatory and manufacturing milestones, which must be met before UNICEF begins procuring doses, including WHO prequalification of a new manufacturing facility.
GSK正在向Bharat Biotech进行技术转让，并在印度药厂于2028年全面接管疫苗生产之前，继续向其供应疫苗的佐剂部分。Gavi和联合国儿童基金会表示，降价预计将于2027年初生效，并建立在将疫苗生产转移至发展中国家制造商的基础上。该协议须满足监管和制造里程碑，包括世卫组织对新制造设施的预认证，这些里程碑必须在联合国儿童基金会开始采购疫苗剂次之前达成。
GSK和Bharat Biotech去年还表示，他们计划到2028年将Mosquirix疫苗价格降至每剂5美元以下。Gavi和联合国儿童基金会去年还达成协议，将印度血清研究所生产的另一种疟疾疫苗价格降低25%。
GSK and Bharat Biotech also said last year they plan to cut the price of the Mosquirix vaccine below $5 per dose by 2028 Gavi and UNICEF also struck a deal last year to cut the price of another malaria vaccine made by the Serum Institute of India by 25%